Intra-Cellular Therapies Price to Book Ratio 2013-2022 | ITCI
Historical price to book ratio values for Intra-Cellular Therapies (ITCI) over the last 10 years. The current price to book ratio for Intra-Cellular Therapies as of July 01, 2022 is 6.56.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Intra-Cellular Therapies Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2022-07-01 |
55.17 |
|
6.54 |
| 2022-03-31 |
61.19 |
$8.43 |
7.26 |
| 2021-12-31 |
52.34 |
$5.10 |
10.26 |
| 2021-09-30 |
37.28 |
$5.98 |
6.23 |
| 2021-06-30 |
40.82 |
$6.81 |
6.00 |
| 2021-03-31 |
33.93 |
$7.54 |
4.50 |
| 2020-12-31 |
31.80 |
$8.16 |
3.90 |
| 2020-09-30 |
25.66 |
$8.85 |
2.90 |
| 2020-06-30 |
25.67 |
$5.68 |
4.52 |
| 2020-03-31 |
15.37 |
$6.50 |
2.36 |
| 2019-12-31 |
34.31 |
$3.51 |
9.77 |
| 2019-09-30 |
7.47 |
$4.11 |
1.82 |
| 2019-06-30 |
12.98 |
$4.65 |
2.79 |
| 2019-03-31 |
12.18 |
$5.24 |
2.33 |
| 2018-12-31 |
11.39 |
$5.79 |
1.97 |
| 2018-09-30 |
21.70 |
$6.46 |
3.36 |
| 2018-06-30 |
17.67 |
$7.14 |
2.48 |
| 2018-03-31 |
21.05 |
$7.74 |
2.72 |
| 2017-12-31 |
14.48 |
$8.32 |
1.74 |
| 2017-09-30 |
15.78 |
$7.36 |
2.15 |
| 2017-06-30 |
12.42 |
$7.82 |
1.59 |
| 2017-03-31 |
16.25 |
$8.13 |
2.00 |
| 2016-12-31 |
15.09 |
$8.67 |
1.74 |
| 2016-09-30 |
15.24 |
$9.23 |
1.65 |
| 2016-06-30 |
38.82 |
$9.85 |
3.94 |
| 2016-03-31 |
27.80 |
$10.47 |
2.65 |
| 2015-12-31 |
53.79 |
$11.04 |
4.87 |
| 2015-09-30 |
40.04 |
$11.67 |
3.43 |
| 2015-06-30 |
31.95 |
$5.81 |
5.50 |
| 2015-03-31 |
23.88 |
$6.36 |
3.76 |
| 2014-12-31 |
17.65 |
$4.09 |
4.32 |
| 2014-09-30 |
13.71 |
$4.56 |
3.01 |
| 2014-06-30 |
16.86 |
$4.72 |
3.57 |
| 2014-03-31 |
18.18 |
$4.88 |
3.72 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.204B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
